drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (allogeneic genetically modified γδ T cells)
drug_description
Donor-derived γδ T cells engineered to express a chimeric antigen receptor (CAR) targeting tumor-expressed HLA-G and to secrete a bispecific T-cell engager (BiTE) that binds CD3 on endogenous T cells, thereby recruiting bystander T cells for additional tumor killing. Intended for relapsed/refractory PD-L1+ solid tumors including NSCLC, TNBC, CRC, and GBM.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor-derived gamma-delta T cells engineered to express a CAR targeting tumor HLA-G and to secrete a CD3-binding bispecific T-cell engager (BiTE). The CAR enables direct, MHC-independent recognition and killing of HLA-G–positive tumor cells, while the secreted BiTE recruits and activates endogenous alpha-beta T cells via CD3 to enhance bystander tumor killing through perforin/granzyme cytotoxicity and cytokine release, with inherently low GVHD risk.
drug_name
HLA-G-CAR.BiTE allogeneic γδ T cells
nct_id_drug_ref
NCT06150885